Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Áåñïëîäíûé áðàê

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #1  
Ñòàðûé 18.08.2004, 15:41
orla orla âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.07.2004
Ñîîáùåíèé: 13
orla *
Vitamini i IUI

Dobrij den,

Na rasnix forumax/internetnix stranichkax ya chitla soobsheniya o tom chto nado sa 3 mesyaza do predpolagaemoj beremennosti nachinat prinimat vitamini (Folievuyu kislotu, vitamini gruppi B, jod). Na drugix ge, ya videla informaziyu o tom, chto prinyatie etix ge vitaminov moget negativno skasatsya na budushem rebenke, ili chto ix prinyatie ne nuzhno.

Xotelos by usnat chto vy ob etom dumaete?
Chto delat pri iskusstvennoj inseminazii - kogda nachinat prinimat vitamini?
Est li kaki libo testi kotorie mogut proverit chego organizmu ne xvataet (kak oni nasivayutsya?)?

Spasibo,

Orla
Îòâåòèòü ñ öèòèðîâàíèåì
  #2  
Ñòàðûé 18.08.2004, 17:11
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,382
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Vitamini i IUI
Óâàæàåìàÿ Îðëà!

ñ ïîìîùüþ òðàíñëèòà ïèñàòü è ïîíèìàòü íàïèñàííîå ëåã÷å [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Âîò êàê âûãëÿäèò Âàøå ñîîáùåíèå:

Äîáðèé äåí,

Íà ðàñíèõ ôîðóìàõ/èíòåðíåòíèõ ñòðàíè÷êàõ ÿ ÷èòëà ñîîáøåíèÿ î òîì ÷òî íàäî ñà 3 ìåñÿçà äî ïðåäïîëàãàåìîé áåðåìåííîñòè íà÷èíàò ïðèíèìàò âèòàìèíè (Ôîëèåâóûó êèñëîòó, âèòàìèíè ãðóïïè Á, ¸ä). Íà äðóãèõ ãå, ÿ âèäåëà èíôîðìàçèûó î òîì, ÷òî ïðèíÿòèå åòèõ ãå âèòàìèíîâ ìîãåò íåãàòèâíî ñêàñàòñÿ íà áóäóøåì ðåáåíêå, èëè ÷òî èõ ïðèíÿòèå íå íóæíî.

Õîòåëîñ áû óñíàò ÷òî âû îá åòîì äóìàåòå?
×òî äåëàò ïðè èñêóññòâåííîé èíñåìèíàçèè - êîãäà íà÷èíàò ïðèíèìàò âèòàìèíè?
Åñò ëè êàêè ëèáî òåñòè êîòîðèå ìîãóò ïðîâåðèò ÷åãî îðãàíèçìó íå õâàòàåò (êàê îíè íàñèâàûóòñÿ?)?

Ñïàñèáî,

Îðëà

Íûíå ðåêîìåíäóåòñÿ ïðèåì 2 ñóáñòàíöèé âñåì áåðåìåííûì: âèòàìèí Â9 (ôîëèåâàÿ ê-òà) è æåëåçî.
Ôîëèåâóþ ðåêîìåíäóåòñÿ ñ ïåðèîäà çà÷àòèÿ íå ìåíåå 400 ìêã â ñóòêè, æåëåçî - 0.8 mg Fe in the first trimester, between 4 and 5 mg in the second trimester, and >6 mg in the third trimester (èëè ñ ó÷åòîì 5-10%âñàñûâàåìîñòè ñóòî÷íàÿ äîçà èîííîãî æåëåçà - 10-20 ìã â ïåðâûé òðèìåñòð, 30-50 ìã - âî âòîðîé, è 60-80 ìã - â òðåòèé).
Îòâåòèòü ñ öèòèðîâàíèåì
  #3  
Ñòàðûé 18.08.2004, 17:23
Àâàòàð äëÿ Melnichenko
Melnichenko Melnichenko âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 26.07.2001
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 117,259
Ñêàçàë(à) ñïàñèáî: 26
Ïîáëàãîäàðèëè 33,619 ðàç(à) çà 32,693 ñîîáùåíèé
Melnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåMelnichenko ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
 ðåãèîíàõ ñ èîäíûì äåôèöèòîì áåðåìåííûì è êîðìÿùèì ðåêîìåíäóþò ïðèåì èîäèäà êàëèÿ 200 ìêã .
__________________
Ã.À. Ìåëüíè÷åíêî
Îòâåòèòü ñ öèòèðîâàíèåì
  #4  
Ñòàðûé 24.08.2004, 14:53
orla orla âíå ôîðóìà Ïîë æåíñêèé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 05.07.2004
Ñîîáùåíèé: 13
orla *
Ñïàñèáî çà îòâåòû. Åùå ìåíÿ èíòåðåñóåò êàêèå âèòàìèíû ñëåäóåò ïèòü ìóæó, ÷òîáû óëó÷øèòü êà÷åñòâî ñïåðìû, ò.ê. ó íåãî âñåãî 5% ïîäâèæíûõ.

Âîçìîæíî ëè óëó÷øèòü êà÷åñòâî ñïåðìû?

Ñïàñèáî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #5  
Ñòàðûé 24.08.2004, 17:11
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,382
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïîïðîáóéòå Ë-(àöåòèë)-êàðíèòèí: íåïëîõî óâåëè÷èâàë ïîäâèæíîñòü â èòàë. èññëåäîâàíèè:

Lenzi A, Sgro P, Salacone P, Paoli D, Gilio B, Lombardo F, Santulli M, Agarwal A, Gandini L. A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia.
Fertil Steril. 2004 Jun;81(6):1578-84.

Åñëè íå ëåíü ïåðåâîäèòü, òî î âëèÿíèè âñÿ÷åñêèõ ïèùåâûõ äîáàâîê ïðè ìóæñêîì áåñïëîäèè ðàññóæäàëè áåëüãèéöû:

Reprod Biomed Online. 2003 Oct-Nov;7(4):385-91.

The role of food supplements in the treatment of the infertile man.

Comhaire FH, Mahmoud A.

Centre for Medical and Urological Andrology, Ghent University Hospital, De Pintelaan, 185, B 9000 Gent, Belgium.

Recently, concerns have been raised about the presumptive increased risk of serious undesirable side effects in children born after IVF and intracytoplasmic sperm injection (ICSI). These treatments must, therefore, be reserved as the ultimate option after evidence-based and cause-directed treatment of the male patient with deficient semen has been exhausted. The present authors found that sperm quality and function improved with the intake of complementary food supplementation using a combination of zinc and folic acid, or the antioxidant astaxanthin (Astacarox), or an energy-providing combination containing (actyl)-carnitine (Proxeed). Also, double blind trials showed that the latter two substances increase spontaneous or intrauterine insemination- (IUI-) assisted conception rates. Extracts of Pinus maritima bark (Pycnogenol), which inhibits the cyclo-oxygenase enzyme, reducing prostaglandin production and inflammatory reaction, and extracts of the Peruvian plant Lepidium meyenii were shown to improve sperm morphology and concentration, respectively, in uncontrolled trials. Linseed (flaxseed) oil contains alfa-linolenic acid and lignans. The former corrects the deficient intake of omega-3 essential fatty acids, which is correlated with impaired sperm motility among subfertile men. Lignans are precursors of enterolacton, which inhibits aromatase and reduces the ratio of 16-OH over 2-OH oestrogen metabolites. The resulting reduction in oestrogen load may favourably influence Sertoli cell function.
Îòâåòèòü ñ öèòèðîâàíèåì
  #6  
Ñòàðûé 25.08.2004, 11:40
Àâàòàð äëÿ Áîðèñ Êàìåíåöêèé
Áîðèñ Êàìåíåöêèé Áîðèñ Êàìåíåöêèé âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 27.07.2001
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,200
Ïîáëàãîäàðèëè 1,529 ðàç(à) çà 1,416 ñîîáùåíèé
Áîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåÁîðèñ Êàìåíåöêèé ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâ. orla!

Íàðóøåíèå ñïåðìàòîãåíåçà (êàê âàðèàíò àñòåíîçîîñïåðìèÿ) íå ÿâëÿåòñÿ äèàãíîçîì. Äóìàþ, ÷òî äëÿ òîãî, ÷òîáû ïðèíÿòü ðåøåíèå î ëå÷åíèè (è î ïðèåìå ÁÀÄ, â òîì ÷èñëå) íåîáõîäèìî, êàê ìèíèìóì ïîïûòàòüñÿ âûÿñíèòü ïðè÷èíó. Âîçìîæíî îíà òàê è íå áóäåò óñòàíîâëåíà è â ýòîì ñëó÷àå ëå÷åíèå áóäåò íàçíà÷åíî ñèìïòîìàòè÷åñêîå.


äëÿ Dr. Vad

Ïî-ìîåìó îñíîâíûå âûâîäû èññëåäîâàíèÿ (Fertil Steril. 2004 Jun;81(6):1578-84. ) ïðèâåäåíû â àíàëèçå òàáëèöû ¹1. Âíèìàòåëüíî ïîñìîòðåâ íà äîâåðèòåëüíûå èíòåðâàëû, äóìàþ, ÷òî âñå ñòàíîâèòñÿ ÿñíûì. Ñëåäóþùèå òàáëèöû è ðåçóëüòàòû â íèõ ïðèâåäåííûå, ïî-ìîåìó ÿâëÿþòñÿ "ñòàòèñòè÷åñêèìè èãðàìè".


The two semen analyses conducted before treatment (T−2 and T0) showed no statistically significant differences in t test for independent samples conducted on semen volume, sperm concentration, motility (total and forward), and morphology. Values measured at the beginning of the treatment (T0) were therefore acceptable as the baseline for further comparisons.
Results at T+3 and the mean of the two analyses at T+6 compared by analysis of variance for repeated measures did not show statistically significant differences for either single patients or the placebo and therapy groups. Mean values at T+6 were then used in the further comparison with values at T0.
Subjects undergoing carnitine therapy showed no improvement in semen volume and sperm concentration and percentage of normal morphology but did have an improvement in total and forward sperm motility as compared with placebo patients (from 23.17 ± 6.50 to 31.11 ± 13.46 and from 14.83 ± 5.17 to 25.00 ± 13.06). However, the differences between the therapy and placebo groups for all the semen variables analyzed were not statistically significant for either analysis of variance for repeated measures or t test for independent samples (on differences between T+6 and T0). Neither did the linear regression analysis model show a statistical significance in the variation observed.
Îòâåòèòü ñ öèòèðîâàíèåì
  #7  
Ñòàðûé 25.08.2004, 16:47
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,382
Ïîáëàãîäàðèëè 33,228 ðàç(à) çà 31,578 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
óâàæàåìûé Áîðèñ Êàìåíåöêèé!

Ìîæåò Âû è ïðàâû, âíèìàòåëüíî ñòàòüþ ñàìó íå ÷èòàë: ïðîñòî ýòî óæå áûëà âòîðàÿ ïóáëèêàöèÿ îò ýòèõ àâòîðîâ è òàêæå áûëè îïóáëèêîâàíû íåêîòîðûå èññëåäîâàíèÿ íà æèâîòíûõ.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 01:51.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.